MARKET

DBVT

DBVT

Dbv Technologies S A
NASDAQ
0.8270
-0.0120
-1.43%
After Hours: 0.8304 +0.0034 +0.41% 16:00 02/27 EST
OPEN
0.8200
PREV CLOSE
0.8390
HIGH
0.8400
LOW
0.8078
VOLUME
91.31K
TURNOVER
0
52 WEEK HIGH
2.370
52 WEEK LOW
0.6500
MARKET CAP
158.91M
P/E (TTM)
-2.5446
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at DBVT last week (0219-0223)?
Weekly Report · 1d ago
Buy Rating Affirmed for DBV Technologies on Strong Viaskin Peanut Patch Clinical Data and Promising Trials
TipRanks · 1d ago
HC Wainwright & Co. Reiterates Buy on DBV Technologies, Maintains $10 Price Target
Benzinga · 6d ago
DBV Technologies to Participate in Upcoming AAAAI 2024 Congress
DBV Technologies to Participate in Upcoming AAAAI 2024 Congress in Washington, D.C. DBV Technologies is a clinical-stage biopharmaceutical company focused on treatments for food allergies. The company will present at the American Academy of Allergy, Asthma, and Immunology Annual Meeting.
Barchart · 02/20 15:30
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Trexade Health (NASDAQ:MEDS) shares rose 207.2% to $14.1 during Tuesday's pre-market session. Biofrontera stock moved upwards by 206.87% in Tuesday's session. RAPT Therapeutics (NASdaq:RAPT) stock declined by 67.3% during the session.
Benzinga · 02/20 13:05
JMP Securities Keeps Their Buy Rating on DBV Technologies SA – American (DBVT)
TipRanks · 02/20 05:45
Weekly Report: what happened at DBVT last week (0212-0216)?
Weekly Report · 02/19 09:03
Buy Rating for DBV Technologies: Viaskin Peanut’s Market Edge Over Xolair
TipRanks · 02/16 20:35
More
About DBVT
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

Webull offers DBV Technologies SA - ADR stock information, including NASDAQ: DBVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DBVT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DBVT stock methods without spending real money on the virtual paper trading platform.